... ," said Cristofanilli. "These findings show the possibility of adding a targeted therapy such as Iressa or others in the EGFR drug class to improve the benefit for hormonal therapy, giving another ...
... , but not predictive to treatment with either therapy.
"Our study found that patients who received Iressa and whose tumors had EGFR mutations will have an improved response rate and progression-free ...
Gefitinib, also known as Iressa, the once-promising targeted therapy for the treatment of nonsmall cell lung cancer, has proven as effective as chemotherapy as a second-line therapy for the disease ...
... to treatment. Patients with the two most typical mutations had vigorous responses to Iressa, but the seven patients found to have atypical mutations had a more limited response. None of the atypical ...
... ) in the treatment of HER-2–positive breast cancer; $1,800 per month for gefitinib (Iressa) for the treatment of lung cancer; and more than $8,000 for a 6-day course of palifermin (Kepivance) in the ...
... EGFR determine whether NSCLC tumors respond to a group of drugs called TKIs, which includes Iressa and Tarceva. Although the response of sensitive tumors to those drugs can be swift and dramatic, ...
HONG KONG, Sept. 17 (UPI) -- Chinese medical scientists say the drug gefitinib (Iressa) should be considered the first-line therapy for non-smoking Asian patients with lung cancer.
... to inhibit the EGF receptor, including erlotinib (trade name Tarceva) and gefitinib (trade name Iressa), are FDA-approved for the treatment of non-small cell lung cancer.
Now, the researchers show ...
... chemotherapy for patients with head and neck cancer. Gefinitib, which also is known by the trade name Iressa, is a targeted therapy against the epidermal growth factor receptor (EGFR) with fewer side ...
... (AP) -- Four years after the government severely restricted its use, the lung cancer drug Iressa may be poised to make a comeback: A study concludes it can slow the deadly disease better than ...
